CW February 2005
Volume 14Issue Number 2 February 2005 ISSN 10593802 The US FDA Approves DOXIL® for Chemotherapy Refractory Ovarian CancerThe US Food and Drug Administration (FDA) has granted full approval to DOXIL® (doxorubicin HCl liposome injection) for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy.
Go to Previous Page Go to Next Page Source & Addtional Reading A. N. Gordon et al., Journal of Clinical Oncology, September 2001. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW February 2005Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
